Floatz logo

Galcanezumab

Tinnitus

Stanford Universitymonoclonal_antibodyPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Tinnitus cohort.

Asset / SponsorPhaseRating
VERAPAMIL SLOW RELEASE
Stanford University
Phase 4BB
Paroxetine
University of California, Irvine
Phase 4BB
Topamax
Stanford University
Phase 4BB
NORAMITRIPTYLINE
Stanford University
Phase 4B
Amitriptyline
Stanford University
Phase 4B

View all 16 →

Same molecule, other indications

Galcanezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
78 / 100
View asset →
glossopharyngeal neuralgiaDormant
BB
Indicative ·
69 / 100
View asset →
migraine disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →